I didn't want these results to get lost in the shoot the breeze...

I didn't want these results to get lost in the shoot the breeze thread. thanks again shane1978

https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12622000570785

"Arm B also showed higher sensitivity (100.00%) up to positive results with Ct 25 and 4-7 days post onset of symptoms,"

just for comparison read jandb85's post 62788773


the importance of this result is that all new testing from all over the world is using ct25 and 4-7 day post onset of symptoms, for registration submissions and validation tests. and once again we have achieved gold std results and this time they are officially published.


to copy from j85, "All in all if Eugeni is pulling 87.75% sensitivity and 100% specificity and the market leader in research above is Lumira DX 82.7% and 96.9%" I agree even at higher ct values Eugeni still shines and picks up the omicron variant as good or better than any test."

I've already posted about the significance of our sensitivity  for our other test to function as multiplex solutions. it is brilliant to see  it in an official document. the significance of the results is that if they are achieved in the European trial and the interim report needed for common list approval, we will have a test available for the European winter.

from announcement

"AnteoTech has focused its resources on a number of promising distribution opportunities in Europe, where clinical trials are advancing. The Company is targeting a Common List registration for the EuGeni COVID-19 RAT by the end of 1H FY23. With clinical pathways in Australia and Europe now well- established, the Company will focus its near-term commercialisation and distribution efforts on those markets."

so 100% sensitivity, 100% specificity to ct 25 published from Alfred trial, common list approval 1H FY23 in time for European winter and distribution networks set up.  European sales in the new year, maybe !!!!